Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Agomelatine for positive and negative symptoms in hospitalized patients with schizophrenia
IRCT20240805062662N1Phase 2Completed
- Sponsor
- Ahvaz Jundishapur University of Medical Sciences
- Start
- Sep 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, triple-blind trial of agomelatine in schizophrenia (2 arms), sponsored by Ahvaz Jundishapur University of Medical Sciences. Primary endpoints: DSM-5, Calgary Schizophrenia Depression Scale and 1 more. Started Sep 2024; status: completed.
02
Drugs
agomelatine
03
Conditions
schizophrenia
Beyond the preview
Go deeper on IRCT20240805062662N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20240805062662N1.